Cargando…

Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis

BACKGROUND AND PURPOSE: The aim of this retrospective study was to compare volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with three-dimensional conformal radiotherapy (3D–CRT) in preoperative chemoradiation for rectal cancers. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Hideomi, Ishihara, Soichiro, Nozawa, Hiroaki, Kawai, Kazushige, Kiyomatsu, Tomomichi, Okuma, Kae, Abe, Osamu, Watanabe, Toshiaki, Nakagawa, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607844/
https://www.ncbi.nlm.nih.gov/pubmed/28934968
http://dx.doi.org/10.1186/s13014-017-0894-9
_version_ 1783265351346159616
author Yamashita, Hideomi
Ishihara, Soichiro
Nozawa, Hiroaki
Kawai, Kazushige
Kiyomatsu, Tomomichi
Okuma, Kae
Abe, Osamu
Watanabe, Toshiaki
Nakagawa, Keiichi
author_facet Yamashita, Hideomi
Ishihara, Soichiro
Nozawa, Hiroaki
Kawai, Kazushige
Kiyomatsu, Tomomichi
Okuma, Kae
Abe, Osamu
Watanabe, Toshiaki
Nakagawa, Keiichi
author_sort Yamashita, Hideomi
collection PubMed
description BACKGROUND AND PURPOSE: The aim of this retrospective study was to compare volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with three-dimensional conformal radiotherapy (3D–CRT) in preoperative chemoradiation for rectal cancers. METHODS AND MATERIALS: In the propensity score-matching analysis of 1:2, we selected 60 patients from the SIB-VMAT group and 120patients from the 3D–CRT group matched pairings out of 145 patients between 2005 and 2015. The regimen of concurrent combined chemotherapy was oral uracil/tegafur plus leucovorin with/without irinotecan. RESULTS: There were no significant differences between the two groups, in pathological complete response rates (pCR) (11% in the 3D–CRT group vs. 17% in the SIB-VMAT group, P = 0.39), pathological response rates (44% vs. 60%, P = 0.77), disease-free survival (P = 0.32), or local control (P = 0.52). The SIB-VMAT method marginally improved the rate of pathological grade 2–3 effects and the OS was significantly better in patients with grade 2–3 effects. Recurrence was seen in 36 patients (30%) in the 3D–CRT group and 19 patients (32%) in the SIB-VMAT group. The first distant recurrence site in the SIB-VMAT group was liver in 6 patients and lung in 8 patients. The obvious radiation-induced late toxicity in the SIB-VMAT group was recto-vesical fistula in two patients. CONCLUSIONS: The SIB-VMAT may be a promising method for preoperative CRT of rectal cancer.
format Online
Article
Text
id pubmed-5607844
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56078442017-09-24 Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis Yamashita, Hideomi Ishihara, Soichiro Nozawa, Hiroaki Kawai, Kazushige Kiyomatsu, Tomomichi Okuma, Kae Abe, Osamu Watanabe, Toshiaki Nakagawa, Keiichi Radiat Oncol Research BACKGROUND AND PURPOSE: The aim of this retrospective study was to compare volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with three-dimensional conformal radiotherapy (3D–CRT) in preoperative chemoradiation for rectal cancers. METHODS AND MATERIALS: In the propensity score-matching analysis of 1:2, we selected 60 patients from the SIB-VMAT group and 120patients from the 3D–CRT group matched pairings out of 145 patients between 2005 and 2015. The regimen of concurrent combined chemotherapy was oral uracil/tegafur plus leucovorin with/without irinotecan. RESULTS: There were no significant differences between the two groups, in pathological complete response rates (pCR) (11% in the 3D–CRT group vs. 17% in the SIB-VMAT group, P = 0.39), pathological response rates (44% vs. 60%, P = 0.77), disease-free survival (P = 0.32), or local control (P = 0.52). The SIB-VMAT method marginally improved the rate of pathological grade 2–3 effects and the OS was significantly better in patients with grade 2–3 effects. Recurrence was seen in 36 patients (30%) in the 3D–CRT group and 19 patients (32%) in the SIB-VMAT group. The first distant recurrence site in the SIB-VMAT group was liver in 6 patients and lung in 8 patients. The obvious radiation-induced late toxicity in the SIB-VMAT group was recto-vesical fistula in two patients. CONCLUSIONS: The SIB-VMAT may be a promising method for preoperative CRT of rectal cancer. BioMed Central 2017-09-21 /pmc/articles/PMC5607844/ /pubmed/28934968 http://dx.doi.org/10.1186/s13014-017-0894-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yamashita, Hideomi
Ishihara, Soichiro
Nozawa, Hiroaki
Kawai, Kazushige
Kiyomatsu, Tomomichi
Okuma, Kae
Abe, Osamu
Watanabe, Toshiaki
Nakagawa, Keiichi
Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title_full Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title_fullStr Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title_full_unstemmed Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title_short Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
title_sort comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (sib-vmat) of 45 gy/55 gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607844/
https://www.ncbi.nlm.nih.gov/pubmed/28934968
http://dx.doi.org/10.1186/s13014-017-0894-9
work_keys_str_mv AT yamashitahideomi comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT ishiharasoichiro comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT nozawahiroaki comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT kawaikazushige comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT kiyomatsutomomichi comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT okumakae comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT abeosamu comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT watanabetoshiaki comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis
AT nakagawakeiichi comparisonofvolumetricmodulatedarctherapyusingsimultaneousintegratedboostssibvmatof45gy55gyin25fractionswithconventionalradiotherapyinpreoperativechemoradiationforrectalcancersapropensityscorecasematchedanalysis